After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
The experts will take votes on whether the FDA should allow seven popular peptides to be added to a list of substances that are safe for compounding by pharmacies
Always follow any specific instructions your doctor or healthcare provider gives you to make sure your sample is collected correctly and your results are as useful as possible
GPx1, 2 and 3 act as homotetramers, whereas GPx4 is functional as a monomer [2]
Acknowledging the potential risks of AI, it is crucial to mention that under certain conditions it can be toxic, potentially cause allergic reactions, mask concussive symptoms, and exacerbate breathing difficulties for those with respiratory issues
